AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Try Now>> See the top stocks recommended by analysts >> Read More on ABBV: AbbVie NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

As the company navigates the post-Humira era, investors and analysts are closely watching its performance and future prospects. According to InvestingPro data, AbbVie stands as a prominent player ...

For most of those years, AbbVie enjoyed lucrative success with Humira. However, the company's revenue has dipped since Humira lost patent exclusivity in 2023, and the stock price has only ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...